Mills Hilla, Acquah Ronald, Tang Nova, Cheung Luke, Klenk Susanne, Glassen Ronald, Pirson Magali, Albert Alain, Hoang Duong Trinh, Van Thang Nguyen
Department of Medical Science, University for Development, Accra, Ghana.
RD Lab, The Hospital Institute for Hebal Research, 50200 Toluca, Mexico, Mexico.
Emerg Med Int. 2022 Jul 15;2022:6449607. doi: 10.1155/2022/6449607. eCollection 2022.
Prostate cancer is a global fatal type of cancer. It is a type of cancer that affect men. Signs and symptoms of the disease include blood in the urine, pain when one micturates, and difficulties in penis erection. Cisplatin chemotherapy is a principal treatment normally given to the prostate cancer patients. Nonetheless, on its own, cisplatin loses efficacy once administered due to liver pass effects and other biochemical attacks. In this paper, we looked at preparation of PCL nanoparticles loaded with cisplatin and their potential for the treatment of prostate cancer. PCL nanoparticles protect cisplatin from biochemical attack, thus increasing drug efficacy. Incorporation of P-glycoprotein inhibitors in PCL nanoparticles (NPs) loaded with cisplatin could improve prostate cancer treatment even more.
前列腺癌是一种全球致死性的癌症类型。它是一种影响男性的癌症。该疾病的体征和症状包括血尿、排尿时疼痛以及阴茎勃起困难。顺铂化疗是通常给予前列腺癌患者的主要治疗方法。然而,顺铂自身给药后会因肝脏首过效应和其他生化攻击而失去疗效。在本文中,我们研究了负载顺铂的聚己内酯纳米颗粒的制备及其治疗前列腺癌的潜力。聚己内酯纳米颗粒可保护顺铂免受生化攻击,从而提高药物疗效。在负载顺铂的聚己内酯纳米颗粒(NPs)中加入P-糖蛋白抑制剂可能会进一步改善前列腺癌的治疗效果。